Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Athersys Inc (ATHX)

Athersys Inc (ATHX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 332,595
  • Shares Outstanding, K 226,255
  • Annual Sales, $ 1,440 K
  • Annual Income, $ -78,760 K
  • 60-Month Beta -1.71
  • Price/Sales 234.11
  • Price/Cash Flow N/A
  • Price/Book 12.24
Trade ATHX with:

Options Overview

Details
  • Implied Volatility 94.52%
  • Historical Volatility 50.18%
  • IV Percentile 4%
  • IV Rank 11.19%
  • IV High 282.21% on 06/23/21
  • IV Low 70.88% on 07/23/21
  • Put/Call Vol Ratio 0.51
  • Today's Volume 236
  • Volume Avg (30-Day) 1,209
  • Put/Call OI Ratio 0.16
  • Today's Open Interest 53,474
  • Open Int (30-Day) 50,168

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate -0.08
  • Number of Estimates 2
  • High Estimate -0.05
  • Low Estimate -0.11
  • Prior Year -0.11
  • Growth Rate Est. (year over year) +27.27%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.4100 +4.26%
on 09/17/21
1.8100 -18.78%
on 09/02/21
-0.1600 (-9.82%)
since 08/17/21
3-Month
1.3500 +8.89%
on 07/19/21
1.8100 -18.78%
on 09/02/21
-0.0800 (-5.16%)
since 06/17/21
52-Week
1.3500 +8.89%
on 07/19/21
3.0300 -51.49%
on 02/04/21
-0.5900 (-28.64%)
since 09/17/20

Most Recent Stories

More News
Do Options Traders Know Something About Athersys (ATHX) Stock We Don't?

Investors need to pay close attention to Athersys (ATHX) stock based on the movements in the options market lately.

ATHX : 1.4700 (-1.34%)
How Aging-Related Conditions Are Increasing The Treatment Burden For Older Patients

/PRNewswire/ -- - The normal aging process is characterized by a progression of physiologic events that occur throughout the life cycle. Changes associated with aging occur throughout the body and are...

LGVN : 3.62 (+0.84%)
CELU : 6.24 (-0.16%)
CWBR : 1.1500 (+2.68%)
GERN : 1.4100 (-0.70%)
ATHX : 1.4700 (-1.34%)
Athersys Partner HEALIOS K.K. Completes Enrollment in the TREASURE Study of MultiStem Treatment for Ischemic Stroke

Athersys, Inc. (NASDAQ: ATHX) announced today that its partner, HEALIOS K.K. ("Healios"), has completed enrollment in its TREASURE study in Japan, evaluating MultiStem(R) (invimestrocel) cell therapy treatment...

ATHX : 1.4700 (-1.34%)
Athersys Partner HEALIOS K.K. Announces Positive Topline Results of MultiStem for Acute Respiratory Distress Syndrome in the ONE-BRIDGE Study

Athersys, Inc. (NASDAQ: ATHX) announced today that its partner in Japan, HEALIOS K.K. (Healios), has released positive topline data from its ONE-BRIDGE clinical trial evaluating the safety and efficacy...

ATHX : 1.4700 (-1.34%)
Athersys and HEALIOS K.K. Announce Advancement of Their MultiStem Commercial Partnership

Athersys, Inc. (NASDAQ: ATHX) and HEALIOS K.K. (Healios) (TSE Mothers: 4593) jointly announced today an expansion and deepening of their partnership to optimize and better align the collaboration structure...

ATHX : 1.4700 (-1.34%)
Athersys and Healios K.K. Announce Advancement of Their MultiStem Commercial Partnership

Athersys, Inc. (NASDAQ: ATHX) and HEALIOS K.K. (Healios) (TSE Mothers: 4593) jointly announced today an expansion and deepening of their partnership to optimize and better align the collaboration structure...

ATHX : 1.4700 (-1.34%)
Athersys to Host Second Quarter Financial Results Call

Athersys, Inc. (Nasdaq: ATHX) will release its second quarter 2021 financial results at approximately 4:00 PM Eastern Time on Monday, August 9, 2021, and will host a conference call shortly thereafter...

ATHX : 1.4700 (-1.34%)
Soft Tissue Repair Global Market Report 2021: COVID-19 Growth And Change

Reportlinker.com announces the release of the report "Soft Tissue Repair Global Market Report 2021: COVID-19 Growth And Change" - https://www.reportlinker.com/p06103738/?utm_source=GNW

ATHX : 1.4700 (-1.34%)
CRY : 23.94 (-2.80%)
MDT : 129.70 (-0.93%)
SNN : 36.83 (-1.55%)
SYK : 273.03 (-1.12%)
ZBH : 146.72 (+0.34%)
New Publication Provides Further Clarity of MultiStem's Mechanism of Action on Modulating the Inflammatory Response in Critical Care Indications

Athersys, Inc. (NASDAQ: ATHX) announced today that data accumulated from several years of preclinical research was published in the peer-reviewed journal Scientific Reports. The publication describes the...

ATHX : 1.4700 (-1.34%)
Athersys to Present at the Bank of America Virtual Healthcare Conference on May 12

Ivor Macleod, Chief Financial Officer of Athersys Inc. (NASDAQ: ATHX), is scheduled to speak at the Bank of America Securities 2021 Virtual Health Care Conference on Wednesday, May 12, 2021 at 12:30 pm...

ATHX : 1.4700 (-1.34%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Athersys, Inc., a late stage biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused primarily on treating critical care indications neurological conditions, cardiovascular diseases, inflammatory and...

See More

Key Turning Points

3rd Resistance Point 1.5833
2nd Resistance Point 1.5367
1st Resistance Point 1.5033
Last Price 1.4700
1st Support Level 1.4233
2nd Support Level 1.3767
3rd Support Level 1.3433

See More

52-Week High 3.0300
Fibonacci 61.8% 2.3882
Fibonacci 50% 2.1900
Fibonacci 38.2% 1.9918
Last Price 1.4700
52-Week Low 1.3500

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar